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Background. The SCID-hu Thy/Liv mouse model of HIV-1 infection is a useful platform for the preclinical evaluation of antiviral
efficacy in vivo. We performed this study to validate the model with representatives of all four classes of licensed
antiretrovirals. Methodology/Principal Findings. Endpoint analyses for quantification of Thy/Liv implant viral load included
ELISA for cell-associated p24, branched DNA assay for HIV-1 RNA, and detection of infected thymocytes by intracellular
staining for Gag-p24. Antiviral protection from HIV-1-mediated thymocyte depletion was assessed by multicolor flow
cytometric analysis of thymocyte subpopulations based on surface expression of CD3, CD4, and CD8. These mice can be
productively infected with molecular clones of HIV-1 (e.g., the X4 clone NL4-3) as well as with primary R5 and R5X4 isolates. To
determine whether results in this model are concordant with those found in humans, we performed direct comparisons of two
drugs in the same class, each of which has known potency and dosing levels in humans. Here we show that second-generation
antiretrovirals were, as expected, more potent than their first-generation predecessors: emtricitabine was more potent than
lamivudine, efavirenz was more potent than nevirapine, and atazanavir was more potent than indinavir. After interspecies
pharmacodynamic scaling, the dose ranges found to inhibit viral replication in the SCID-hu Thy/Liv mouse were similar to those
used in humans. Moreover, HIV-1 replication in these mice was genetically stable; treatment of the mice with lamivudine did
not result in the M184V substitution in reverse transcriptase, and the multidrug-resistant NY index case HIV-1 retained its drug-
resistance substitutions. Conclusion. Given the fidelity of such comparisons, we conclude that this highly reproducible mouse
model is likely to predict clinical antiviral efficacy in humans.
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Licensed Antiretrovirals. PLoS ONE 2(8): e655. doi:10.1371/journal.pone.0000655
INTRODUCTION
The SCID-hu mouse model, in which human lymphoid organs are
implanted into severe-combined immunodeficient (SCID) mice, was
designed by McCune et al. [1] to provide a small animal model for
the study of human hematopoiesis. It has also facilitated study of the
pathogenesis of HIV-1 in human hematolymphoid organs [2–7] and
evaluation of anti-HIV-1 compounds in vivo [2,8,9]. In this model,
SCID mice are implanted with a variety of human fetal organs,
including bone, liver, thymus, lymph node, and spleen. The fetal
implants become tolerant of the mouse environment, and re-
ciprocally, growth of the human tissue is permitted by the
immunocompromised status of the recipient SCID mouse [6].
The SCID-hu Thy/Liv mouse, first reported by Namikawa et
al. in 1990 [10], is generated by coimplanting human fetal thymus
and liver beneath the mouse kidney capsule. In a highly
reproducible manner, these organs fuse, become vascularized,
and grow into a stable organ termed ‘‘Thy/Liv,’’ reaching a total
mass of 100–300610
6 human cells in 18 weeks. The Thy/Liv
implant reproduces the differentiation, proliferation, and function
of human hematopoietic progenitor cells derived from the fetal
liver within the human thymus. The implants possess histologically
normal cortical and medullary compartments that sustain multi-
lineage human hematopoiesis for 6–12 months [10,11], generating
a continuous source of CD4-expressing thymocytes that can serve
as target cells for HIV-1 infection and replication. Importantly for
a model of antiviral chemotherapy, 50–60 SCID-hu Thy/Liv mice
can be made with tissues from a single fetal donor, and the Thy/
Liv implant is amenable to experimental manipulation and
infection with HIV-1.
The Thy/Liv implants support viral replication after inocula-
tion of HIV-1 by direct injection [3], and thymocyte depletion
occurs with both molecular clones and clinical isolates of HIV-1 in
3–5 weeks [12–16]. This depletion includes loss of CD4
+CD8
+
(double-positive, DP) immature cortical thymocytes and a decrease
in the CD4/CD8 ratio in the thymic medulla. There is evidence
for both indirect, apoptotic destruction of uninfected thymocytes
and direct infection and destruction of CD3
2CD4
+CD8
2
intrathymic T-progenitor cells, which severely disrupts thymocyte
maturation [17,18]. Infection of human thymus with HIV-1
induces IFN-a secretion from plasmacytoid dendritic cells, which
upregulates MHC class I (MHC-I) expression on DP thymocytes,
where expression is normally low [19].
The administration of nucleoside and nonnucleoside reverse
transcriptase (RT) inhibitors to these mice results in dose-dependent
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MHC-I upregulation, and protection of CD4
+ cells within the
implanted human tissue [8,9,20]. The model has been also used to
evaluate new classes of HIV-1 inhibitors, such as bicyclam [21] and
oligonucleotide [22] inhibitorsofHIV-1 entry,the nucleosideanalog
29-deoxy-39-oxa-49-thiocytidine (dOTC) [20], and an oxime-piper-
idine CCR5 antagonist [23]. This is the first animal model in which
the action of candidate anti-HIV-1 compounds can be tested within
the setting of an intact HIV-1-infected human target organ.
We use a standardized protocol described by Rabin et al. [8] for
evaluation of antiviral agents against HIV-1 in the SCID-hu Thy/
Liv mouse model. Drugs can be administered by various routes
(oral, subcutaneous, intraperitoneal, or by mini-osmotic pump)
before or after virus inoculation and continued for 2–6 weeks.
Mice are challenged with titrated inocula of various HIV-1
isolates, and endpoint analyses include quantification of viral
protein by p24 ELISA and viral RNA by branched DNA assay,
quantification and isolation of replication-competent virus by
cocultivation after limiting dilution, and assessment of the effects
on human thymocyte subpopulations by flow cytometry [8].
The SCID-hu Thy/Liv model has also been employed by us and
by others for in vivo studies of HIV-1 pathogenesis. The roles of HIV-
1 nef [24–26], other accessory genes [24], and the Rev–Rev
responsive element [27] have been explored as well as the expression
of HIV-1 coreceptors (CXCR4 and CCR5) on thymocytes [28,29]
and the effects of coreceptor usage on viral tropism and pathogenesis
[16,28,30–32]. The CXCR4-utilizing (X4) strain NL4-3 replicates
quickly and extensively in thymocytes in the cortex and medulla,
causing significant thymocyte depletion [16]. In contrast, the CCR5-
utilizing (R5) strain Ba-L initially infects stromal cells, including
macrophages, in the thymic medulla without any obvious pathologic
consequences for 3–4 weeks, after which the infection slowly spreads
through the thymocyte populations and results in slowly progressing
thymocyte depletion after 6 weeks. In addition, three R5 viruses
isolated from rapid AIDS progressors lacking X4 strains were much
less pathogenic than NL4-3 in SCID-hu Thy/Liv mice, suggesting
that R5 virus-mediated rapid disease progression is associated with
host, not viral, factors [30]. The lab-adapted LAI/IIIB isolate and its
associated infectiousmolecularclones(e.g.,HXB2)failtoreplicatein
Thy/Liv implants, and this impairment has been mapped to
a specific amino acid change in the crown region of V3 in Env
[33,34]. The model has also been used to study immune
reconstitutionand recoveryofhematopoieticcolony-forming activity
in HIV-1-infected implants after treatment of mice with potent
combination antiretroviral therapy [35–37].
Given the potential correlations between virus-host interactions
in the Thy/Liv implant and in humans, we wanted to determine
whether the SCID-hu Thy/Liv mouse model predicts antiretro-
viral efficacy in humans for representatives of all four classes of
currently licensed drugs. Does it, for instance, yield data that
reflect the greater potency of more recently developed drugs than
their first-generation predecessors in each class? In vivo models are
far more stringent than cell culture-based assays for demonstrating
drug activity, particularly in the case of orally delivered drugs as
they must be absorbed by the gastrointestinal tract without
degradation, enter the blood and circulate with sufficient half-lives,
and penetrate solid target organs at concentrations high enough to
be potently efficacious. The greater potency of the second-
generation drugs is likely the result of a combination of greater in
vitro potency and superior pharmacokinetics. In vitro virus-cell
culture systems would likely predict greater potency, but only in
vivo studies can demonstrate sustained plasma half-life or superior
oral bioavailability. To determine such relative potency in vivo,
head-to-head comparisons of two drugs in the same class were
performed in SCID-hu Thy/Liv mouse cohorts each made with
tissues from a single donor. We observed that the more recent
drugs in each class were significantly more potent than their
predecessors. We conclude from such comparisons with licensed
antiretrovirals that this well-established model is likely to predict
clinical antiviral efficacy in humans for other members of these
classes and possibly other drug classes as well.
MATERIALS AND METHODS
Viruses
The following reagents were obtained through the AIDS Research
and Reference Reagent Program, Division of AIDS, NIAID, NIH:
pNL4-3 [38] from Malcolm Martin and HIV-1 Ba-L [39] from
Suzanne Gartner, Mikulas Popovic, and Robert Gallo. A working
stock of NL4-3 was prepared in 293T cells by calcium phosphate
transfection. A T-20-sensitive NL4-3 (NL4-3 D36G) was altered
by site-directed mutagenesis to match the consensus sequence at
amino acid position 36 (aspartic acid replaced by glycine) [40,41].
The R5X4 AZT-resistant clinical HIV-1 isolate JD [42] was
kindly provided by Mike McCune, and the multidrug-resistant
(MDR) R5X4 NY index case isolate [43] by Hiroshi Morhi and
Martin Markowitz. The clinical isolates were prepared and titrated
by limiting dilution in phytohemagglutin-activated peripheral
blood mononuclear cells.
Antiretroviral drugs and mouse dosing
The antiretroviral drugs lamivudine (3TC), emtricitabine [(–)-
FTC], nevirapine, efavirenz, indinavir, and atazanavir were kindly
supplied by Opendra Sharma and the AIDS Reagent Program.
Dosing solutions were prepared in sterile water for injection or
Dulbecco’s phosphate-buffered saline, and groups of 5–8 mice
were treated by oral gavage (200 ml per dose) with an 18-gauge62-
inch feeding needle twice daily at 7:00 AM and 6:00 PM for the
duration of the infection period (2–6 weeks depending on the
HIV-1 isolate). Enfuvirtide (T-20) was purchased from a pharmacy,
prepared in sterile water, and administered by twice-daily
subcutaneous injection (200 ml per dose).
Implantation and inoculation of SCID-hu Thy/Liv
mice
Human fetal thymus and liver were obtained through services
provided by a nonprofit organization (Advanced Bioscience
Resources, Alameda, CA) in accordance with federal, state, and
local regulations. Coimplantation of thymus and liver fragments
under the kidney capsule to create SCID-hu Thy/Liv mice and
inoculation of the Thy/Liv implants with HIV-1 was carried out
as described [8,10]. Male C.B-17 SCID (model #CB17SC-M,
homozygous, C.B-Igh-1
b/IcrTac-Prkdc
scid) mice were obtained at
6–8 weeks of age from Taconic (Germantown, NY), and cohorts
of 50–60 SCID-hu Thy/Liv mice were implanted with tissues
from a single donor. Implants were inoculated 18 weeks after
implantation with 50 ml of stock virus (500–2,000 TCID50)o r
RPMI 1640 medium (mock infection) by direct injection after
surgical exposure of the implanted kidney of anesthetized mice.
Animal protocols were approved by the UCSF Institutional
Animal Care and Use Committee.
Implant collection and viral load quantification
The Thy/Liv implants were collected from euthanized mice, and
single-cell suspensions were prepared by dispersing the implant
through nylon mesh and processed for p24 ELISA, bDNA assay,
and FACS analysis as described [8,20]. Unless specified otherwise,
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14 days after JD inoculation, and 42 days after Ba-L inoculation.
Flow cytometry
Implant cells were stained with phycoerythrin cyanine dye CY7-
conjugated anti-CD4 (BD Biosciences, San Jose, CA), phycoerythrin
cyanine CY5.5-conjugated anti-CD8 (Caltag Laboratories, Burlin-
game, CA), allophycocyanin cyanine CY7-conjugated anti-CD3
(eBiosciences, San Diego, CA), and phycoerythrin-conjugated anti-
W6/32 (DakoCytomation, Glostrup, Denmark. Cells werefixed and
permeabilized with 1.2% paraformaldehyde and 0.5% Tween 20,
stained with fluorescein isothiocyanate-conjugated anti-p24 (Beck-
man Coulter, Fullerton, CA), and analyzed on an LSR II (BD
Biosciences). After collecting 100,000 total cell events, percentages of
marker-positive (CD4
+,C D 8
+, and DP) thymocytes in the implant
samples were determined by first gating on a live lymphoid cell
population identified by forward- and side-scatter characteristics and
then by CD3 expression. W6/32-positive mean fluorescence
intensity (MFI) of DP thymocytes was determined, and CD4/CD8
ratios were calculated by dividing the percentage of CD4
+ cells by
the percentage of CD8
+ cells for each individual implant.
Statistical analysis
Results are expressed as the mean6SEM for each mouse group.
Nonparametric statistical analyses were performed by use of the
Mann-Whitney U test. Data for mice in each group were
compared to those for untreated infected mice, and p values
#0.05 were considered statistically significant.
RESULTS
Viral load and prophylactic antiviral efficacy are
highly reproducible among mouse cohorts each
made with tissues from a single donor
The levels of HIV-1 RNA and p24 in the Thy/Liv implants of
untreated- and 3TC-treated SCID-hu Thy/Liv mice were highly
reproducible among seven different mouse cohorts infected with
the same stock of HIV-1 NL4-3 (Figure 1). In seven consecutive
experiments, with mice in a given cohort constructed from human
fetal tissue from a single donor, mean cell-associated HIV-1 RNA
ranged from 5.2–6.3 log10 copies per 10
6 cells (Figure 1A), and
mean p24 ranged from 640–1,700 pg per 10
6 cells (Figure 1B).
There was also good correspondence between viral RNA and p24
Figure 1. Implant viral loads in untreated- and 3TC-treated SCID-hu Thy/Liv mice are highly reproducible, and 3TC treatment after HIV-1
inoculation is nearly as effective as prophylactic treatment. A, HIV-1 RNA in Thy/Liv implants of untreated mice and mice treated by twice-daily oral
gavage with 3TC at 30 mg/kg per day beginning 1 day before inoculation with NL4-3 (means6SEM) Each experiment was performed in a mouse
cohort made with tissues from a single donor. B, Implant p24 for the same groups as in panel A. C, Implant HIV-1 RNA in mice treated with 3TC
beginning on day 21, day +1, day +3, and day +7 with respect to inoculation with the indicated HIV-1 strains. D, Implant p24 for the same groups as
in panel C. Implants were collected 21 days after inoculation for NL4-3, 14 days for JD, and 42 days for Ba-L. *p#0.05, compared with untreated mice
for 5–7 mice per group.
doi:10.1371/journal.pone.0000655.g001
Validation of SCID-hu Model
PLoS ONE | www.plosone.org 3 August 2007 | Issue 8 | e655Figure 2. 3TC treatment of HIV-1 JD-infected SCID-hu Thy/Liv mice inhibits viral replication and protects implants from virus-mediated
thymocyte depletion. Mice were treated by twice-daily oral gavage with 3TC at 300 mg/kg per day beginning on day +1 after inoculation, and Thy/
Liv implants were collected 14, 21, and 28 days after inoculation. Antiviral efficacy was assessed by determining HIV-1 RNA (A), p24 (B), Gag-p24
+
thymocytes (C), and MHC-I expression on DP thymocytes (D). Thymocyte protection was assessed by total implant cellularity (E), thymocyte viability
(F), percentage of DP thymocytes (G), and CD4/CD8 ratio (H) for 3TC-treated mice versus untreated mice (means6SEM). *p#0.05, compared with
untreated mice for 5–7 mice per group.
doi:10.1371/journal.pone.0000655.g002
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mice in experiment 6 and highest for those in experiments 3 and
5). In the seven experiments, 3TC treatment beginning 1 day
before virus inoculation reduced HIV-1 RNA in the implants by
1.2–2.1 log10 (94%–99%) (Figure 1A) and p24 by 77%–92%
(Figure 1B) compared to untreated mice in the same experiment.
Importantly, HIV-1 NL4-3 replication in these mice was
genetically stable over the 21-day infection period; there was no
evidence of the RT M184V substitution in viral RNA amplified by
RT-PCR and sequenced from 32 of 32 Thy/Liv implants
collected from mice treated with 3TC in these seven experiments
(data not shown). The lack of resistance development is most likely
the result of the limited time before virus-mediated thymocyte
depletion becomes severe enough to limit the number of target
cells available for infection. We view the genetic stability of the
viruses over several weeks as an asset because our results are not
confounded by the rapid development of antiviral resistance,
particularly against drugs for which only one amino acid
substitution is sufficient for high-level resistance.
Postexposure dosing also reduces viral load and
prevents virus-mediated thymocyte depletion
Initiation of 3TC treatment 1 or 3 days after NL4-3 inoculation
was nearly as effective at reducing implant viral RNA (Figure 1C)
and p24 (Figure 1D) as was prophylactic treatment with treatment
beginning 1 day before inoculation. This was also true for mice
inoculated with the clinical R5X4 isolate JD and treated with 3TC
beginning 3 days after inoculation. Treatment of mice inoculated
with the R5 isolate Ba-L, which replicates in Thy/Liv implants
with slower kinetics than does X4 HIV-1 NL4-3 [16], was highly
effective at reducing implant viral RNA and p24 even when
initiation was delayed until 7 days after inoculation.
To determine whether postexposure dosing also prevents
thymocyte depletion, SCID-hu mice were inoculated with HIV-
1 JD and treated twice daily with 3TC at 300 mg/kg per day in
a time-course study in which implants were collected at weekly
intervals up to 28 days after inoculation. By that point, the
implants from untreated mice had become severely depleted of
thymocytes. As expected, 3TC-treated mice had significant
reductions in viral RNA (Figure 2A), p24 (Figure 2B), Gag-p24
+
thymocytes (Figure 2C), and IFN-a-induced MHC-I expression on
DP thymocytes (Figure 2D), compared to untreated mice at all
three times. Reductions in viral load by 3TC were accompanied
by virtually complete protection of the Thy/Liv implants from
thymocyte depletion, in terms of total cellularity (Figure 2E),
thymocyte viability (Figure 2F), percentage of DP thymocytes
(Figure 2G), and CD4/CD8 ratio (Figure 2H). Flow cytometric
analysis of representative implants obtained 28 days after in-
oculation with HIV-1 JD showed severe depletion of DP and
CD4
+ thymocytes in an untreated mouse and nearly complete
protection from thymocyte depletion in one mouse treated with
3TC (Figure 3).
Head-to-head comparisons of antiretroviral drugs at
multiple dosage levels show relative potency
In the course of preclinical antiviral drug development, it is often
important to determine whether a newly discovered agent is more
potent than an existing, perhaps licensed, drug in the same class. To
that end, we produced cohorts of SCID-hu Thy/Liv mice that were
large enough for head-to-head comparisons of two drugs at multiple
(typically three) dosage levels against one virus isolate. When the
nucleoside analogs (–)-FTC and 3TC were compared, (–)-FTC was
more potent at the same dosage levels, with greater reductions in
viral RNA at 30 mg/kg per day (p=0.035) (Figure 4A) and greater
reductions in p24 at 10 mg/kg per day (p=0.025) and 30 mg/kg
perday(p=0.009)(Figure4B).Thep24levelsinmicetreatedwith(–
)-FTC at 30 mg/kg per day were 1% that of mice treated with 3TC
at the same dose (1,300 pg per 10
6 cells in untreated mice versus
1.2 pg per 10
6 cells for (–)-FTC and 110 pg per 10
6 cells for 3TC)
(Figure 4B). Good protection from thymocyte depletion was
observed at all three dosage levels for both drugs (Figure 4C).
In another experiment, the nonnucleoside RT inhibitor
efavirenz was directly compared with nevirapine. Efavirenz was
approximately 10 times more potent than nevirapine, as
demonstrated by similar reductions in viral RNA (Figure 5A)
and p24 (Figure 5B) and by thymocyte protection (Figure 5C) in
groups treated with 300 mg/kg per day of nevirapine compared to
30 mg/kg per day of efavirenz.
Finally, the second-generation protease inhibitor atazanavir was
3–10 times more potent than indinavir in NL4-3-infected SCID-
Figure 3. 3TC treatment protects HIV-1 JD-infected Thy/Liv implants from thymocyte depletion. Flow cytometric analysis of representative
implants stained for CD4 and CD8 obtained 28 days after inoculation with HIV-1 JD shows severe depletion of DP and CD4+ thymocytes in an
untreated mouse and nearly complete protection from thymocyte depletion by 3TC treatment (300 mg/kg per day beginning on day +1 after
inoculation).
doi:10.1371/journal.pone.0000655.g003
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SCID-hu Thy/Liv mice. Mice were treated by twice-daily oral gavage
with 3TC or (–)-FTC at 10, 30, and 100 mg/kg per day beginning on day
–1. Antiviral efficacy was assessed by determining HIV-1 RNA (A) and
p24 (B), and thymocyte protection was assessed by percentage of DP
thymocytes (C) (means6SEM). *p#0.05, compared with untreated mice
for the number of mice indicated under each bar.
doi:10.1371/journal.pone.0000655.g004
Figure 5. Efavirenz is more potent than nevirapine against HIV-1
NL4-3 in SCID-hu Thy/Liv mice. Mice were treated by twice-daily oral
gavage with nevirapine or efavirenz at the indicated dosage levels
beginning on day 21. Antiviral efficacy was assessed by determining
HIV-1 RNA (A) and p24 (B), and thymocyte protection was assessed by
percentage of DP thymocytes (C) (means6SEM). *p#0.05, compared
with untreated mice for the number of mice indicated under each bar.
doi:10.1371/journal.pone.0000655.g005
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(p=0.006) with atazanavir than with indinavir at 300 mg/kg per
day (5.3 log10 copies per 10
6 cells in untreated mice versus ,1.5
log10 copies per 10
6 cells for atazanavir and 4.6 log10 copies per
10
6 cells for indinavir) (Figure 6A). The p24 levels in mice treated
with atazanavir at 100 mg/kg per day were 5% (p=0.029) that of
mice treated with indinavir at the same dose (400 pg p24 per 10
6
cells in untreated mice versus 19 pg p24 per 10
6 cells for
atazanavir and 380 pg p24 per 10
6 cells for indinavir) (Figure 6B).
There was comparable protection from thymocyte depletion for
the drugs at 100 and 300 mg/kg per day (Figure 6C).
T-20 causes dose-dependent reductions in implant
viral load
Although we did not perform this experiment as a direct
comparison with another HIV-1 fusion inhibitor, we are including
these data to complete the interspecies scaling analysis described in
the next section with a fourth class of antiretroviral (T-20).
Treatment of NL4-3 D36G-infected SCID-hu Thy/Liv mice with
T-20 by twice-daily subcutaneous injection resulted in dose-
dependent reductions of both HIV-1 RNA and p24, reducing viral
RNA by 3.3 log10 copies per 10
6 cells and p24 to undetectable
levels at 100 and 30 mg/kg per day (Figure 7).
Inhibitory drug dosage levels are comparable
between SCID-hu Thy/Liv mice and humans
The SCID-hu Thy/Liv mouse has the advantage of having
human, not mouse, cells as the targets of antiretroviral uptake and
action, but the pharmacokinetics of antiretrovirals in the mouse
have the potential to be significantly different from those in
humans. Small mammals usually eliminate drugs faster than large
mammals [44], and toxic endpoints for therapeutics administered
systemically to animals scale well between species when doses are
normalized to body surface area [45]. To determine whether the
doses found inhibitory in the SCID-hu Thy/Liv mouse bear any
relation to those used clinically in humans, an interspecies scaling
factor of 12.3 [46] was applied to generate mouse equivalent doses.
Figure 6. Atazanavir is more potent than indinavir against HIV-1 NL4-
3 in SCID-hu Thy/Liv mice. Mice were treated by twice-daily oral
gavage with indinavir or atazanavir at 100, 300, and 1000 mg/kg per
day beginning on day 21. Antiviral efficacy was assessed by
determining HIV-1 RNA (A) and p24 (B), and thymocyte protection
was assessed by percentage of DP thymocytes (C) (means6SEM).
*p#0.05, compared with untreated mice for the number of mice
indicated under each bar.
doi:10.1371/journal.pone.0000655.g006
Figure 7. T-20 causes dose-dependent reductions in viral load in HIV-
1 NL4-3 D36G-infected SCID-hu Thy/Liv mice. Mice were treated by
twice-daily subcutaneous injection with T-20 at 10, 30, and 100 mg/kg
per day beginning on day 21. Antiviral efficacy was assessed by
determining cell-associated HIV-1 RNA and p24. Data are expressed as
means6SEM; *p#0.05 for treated mice versus untreated mice by the
Mann-Whitney U test for the number of mice indicated under each bar.
doi:10.1371/journal.pone.0000655.g007
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weight ratio between mice (0.0066 m
2/0.02 kg) and humans
(1.6 m
2/60 kg); consequently, 12.3 times more drug is required in
the mouse to be comparable to the dose in humans. When
currently approved dosage levels for humans of each antiretroviral
drug are adjusted for this difference, the adjusted dosage levels
were similar to those that cause 0.9–3.7 log10 reductions in viral
RNA in the SCID-hu Thy/Liv mouse (Table 1). Thus, not only is
the model predictive of relative potency within these drug classes,
it might also be useful in determining approximate dosing ranges
for effective use in humans.
Multidrug-resistant NY index case HIV-1 replicates
and depletes thymocytes with kinetics comparable
to HIV-1 NL4-3
A key test of any new class of antiretroviral drug is a demonstration
of potent activity against HIV-1 with known drug-resistance
mutations. We reported the activity of the 3TC analog dOTC
against 3TC-resistant HIV-1 NL4-3/M184V in the SCID-hu
Thy/Liv model [20]. Here we report that the MDR NY index
case HIV-1, which was isolated from a patient with highly rapid
progression to AIDS [43], replicates with kinetics similar to HIV-1
NL4-3 in SCID-hu Thy/Liv mice (Figure 8A–D) resulting in
severe thymocyte depletion by 28 days after inoculation
(Figure 8E–H). The lower viral loads for the NY index case
isolate compared to NL4-3 at day 28 are most likely the result of
somewhat faster thymocyte depletion and thus greater loss of
target cells for viral replication.
Additional evidence that HIV-1 replication is genetically stable
within the 28-day infection period was provided by sequence
analysis of implant viral RNA showing that the MDR NY index
case isolate [43] retained the full complement of drug-resistance
amino acid substitutions of the original inoculum (data not shown).
These data show that this MDR clinical isolate can readily be used
as a challenge virus in the SCID-hu Thy/Liv model for in vivo
studies of new classes of antiretroviral drugs with activity against
HIV-1 that is resistant to currently licensed antiretrovirals.
DISCUSSION
The SCID-hu Thy/Liv mouse is an efficient model for the study of
HIV-1 infection and for the preclinical evaluation of potential
antiretrovirals. Here we show that this model provides a validated
platform for reproducible viral infectivity and drug-mediated
reductions in viral load in vivo. We also show that the model is
especially valuable for direct, head-to-head comparisons of the
potency and effective dose ranges of existing antiretroviral drugs.
In consecutive experiments performed in different SCID-hu
mouse cohorts infected with the same stock of HIV-1 NL4-3, we
observed a range in mean HIV-1 RNA of only 1.1 log10 copies per
10
6 cells. Reproducible reductions in viral load were also observed
after oral administration of 3TC. Although our standardized
protocol calls for prophylactic treatment 1 day before virus
inoculation to maximize the potential for discerning antiviral
efficacy of new drugs in initial in vivo tests, we show here that
postexposure drug initiation (beginning 1, 3, or 7 days after HIV-1
inoculation) also renders potent antiviral efficacy. Importantly,
potent therapeutic efficacy, in terms of both inhibition of viral
replication and virtually complete protection from virus-mediated
cytopathicity and thymocyte depletion, was also demonstrated in
3TC-treated mice infected with the highly cytopathic R5X4
isolate, JD. In addition, we have minimized one potential
experimental variable by inoculating the mice at a uniform time
point 18 weeks after implantation.
The goal of this study was to validate the SCID-hu Thy/Liv
model for use in drug discovery efforts by determining the efficacy
of different classes of FDA-approved antiretroviral drugs. Antiviral
efficacy in this model is demonstrated by dose-dependent
reductions in viral load as well as dose-dependent protection of
CD4
+ T cells from virus-mediated depletion. Assessment of
thymocyte percentage and viability is particularly important for
proving that the observed antiviral activity is not merely the result
of cytotoxicity to the Thy/Liv implant just as the selectivity index
(ratio of cytotoxic to inhibitory concentration) is important for
assessing antiviral activity in vitro.
As new antiretroviral drugs in existing drug classes are
developed to improve upon antiviral potency or to limit in vivo
toxicity, direct comparisons of the existing drug and the new drug
in single SCID-hu mouse cohorts represent a powerful preclinical
tool for the prediction of improved efficacy in human patients. To
accomplish this, we produced cohorts of SCID-hu Thy/Liv mice
that were large enough for comparison of two drugs at three
dosage levels against one virus isolate. For studies of viral
pathogenesis and hematopoietic reconstitution, a relatively small
number of animals can generate sufficient replicate points for
analysis. In contrast, preclinical antiviral evaluations require
groups of animals sufficiently large to demonstrate statistical proof
of efficacy in vivo. Two-drug, three-dose comparisons are made
possible by our unique ability to construct large (50–60-mouse)
SCID-hu cohorts with tissues from a single donor, which permits
Table 1. Antiretroviral drug dosage levels adjusted for difference in surface area-to-body weight ratio between mice and humans
..................................................................................................................................................
Drug Human dosage regimen
a
Human dosage
b
(mg/kg per day)
Mouse equivalent dosage
c
(mg/kg per day)
Calculated reduction in implant
HIV-1 RNA
d (log10 copies)
3TC 150 mg twice daily 5.0 62 1.9
(–)-FTC 200 mg once daily 3.3 41 2.3
nevirapine 400 mg once daily 6.7 82 0.9
efavirenz 600 mg once daily 10 123 3.7
indinavir 800 mg three times daily 40 490 1.2
atazanavir 400 mg once daily 6.7 82 1.4
T-20 90 mg twice daily 3.0 37 3.2
aFrom ref. [56].
bBased on 60 kg adult human weight and 20 g mouse weight.
cHuman dosage612.3 (fold difference in surface area to body weight between mice and humans; from ref. [45,46].
dCalculated by linear regression of the viral RNA data shown in Figures 3–6 at the equivalent mouse dosage level.
doi:10.1371/journal.pone.0000655.t001
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PLoS ONE | www.plosone.org 8 August 2007 | Issue 8 | e655Figure 8. Multidrug-resistant (MDR) NY index case HIV-1 replicates and depletes thymocytes with kinetics comparable to HIV-1 NL4-3 in SCID-
hu Thy/Liv mice. Viral replication assessed by determining HIV-1 RNA (A), p24 (B), Gag-p24
+ thymocytes (C), and MHC-I expression on DP thymocytes
(D). Thymocyte protection was assessed by total implant cellularity (E), thymocyte viability (F), percentage of DP thymocytes (G), and CD4/CD8 ratio
(H) for NL4-3 versus MDR NY index case HIV-1-infected mice (means6SEM). *p#0.05, compared with untreated mice for 7 mice per group.
doi:10.1371/journal.pone.0000655.g008
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power. Given such group sizes and appropriate controls, it is
possible to assign effective antiviral dose ranges with statistical
precision [8]. Among animal models for HIV-1, this ability is
unique: nonhuman primate models (i.e., SIV- or SHIV-infected
rhesus macaques) cannot provide dosing groups of such size and
cannot achieve the same statistical power and relatively lower cost
per animal. There are several recent reports on the infection of
humanized Rag2
2/2cc
2/2 (RAG-hu) [47–50] and NOD/SCID
BLT mice [51] with HIV-1, but there are no reports yet published
on the evaluation of antiretroviral efficacy in these models, and it
has not yet been demonstrated that 50–60 mice can be generated
with the CD34
+ hematopoietic stem cells from a single donor. In
a recent review [52], Manz states that one of the challenges these
CD34
+-reconstituted mouse models face is that usually less than 10
mice can be transplanted from one human graft.
In the experiments presented here, the second-generation
antiretrovirals in each drug class were more potent than their
first-generation predecessors. Thus, (–)-FTC was more potent than
3TC, the nonnucleoside RT inhibitor efavirenz was more potent
than nevirapine, and the protease inhibitor atazanavir was more
potent than indinavir. The greater potency of the newer drugs in
SCID-hu Thy/Liv mice is consistent with their observed greater
potency in HIV-1-infected individuals. The nonnucleoside RT
inhibitor (–)-FTC has greater potency than 3TC because the (–)-
FTC-triphosphate is incorporated 10 times more efficiently than
3TC-triphosphate during HIV-1 RT-catalyzed RNA-dependent
DNA synthesis [53]. The 10-fold greater potency of efavirenz
compared to nevirapine in SCID-hu mice is entirely predictive of
the superior oral bioavailability and plasma half-life characteristics
of efavirenz [54], which allow for once-daily dosing in humans as
the current standard of care compared with twice-daily dosing for
nevirapine. Finally, the greater potency of atazanavir over
indinavir in SCID-hu mice can be explained by a combination
of its greater in vitro potency and oral bioavailability, allowing
once-daily dosing [55]. Taken together, these comparisons of
licensed antiretrovirals in each major class suggest that the SCID-
hu Thy/Liv model may also predict clinical antiviral efficacy in
humans. These results extend an earlier validation of the model
with the nucleoside analogs zidovudine and dideoxyinosine [8].
The predictive nature of SCID-hu mouse efficacy is further
supported by the dosage levels required to achieve log order
reductions in implant viral load when adjusted for the difference in
surface area-to-body weight ratio between mice and humans.
Upon initial examination, the effective dosage level of 1,000 mg/
kg per day for indinavir in the mice seems overly high until such
an adjustment is made and the very high human daily dosage of
2.4 g (800 mg three times a day) is taken into consideration.
Predictiveness of the SCID-hu Thy/Liv model for the behavior
of HIV-1 in humans can be extended beyond antiretroviral
efficacy to simple kinetics of viral replication and virus-mediated
cytopathicity. AZT-resistant (JD) and MDR NY index case R5X4
clinical isolates replicate and cause thymocyte depletion with
kinetics comparable to HIV-1 NL4-3. The data presented here
show that drug-resistant clinical isolates can readily be used as
challenge viruses in the SCID-hu Thy/Liv model for in vivo studies
of new classes of antiretroviral drugs with activity against HIV-1
that is resistant to currently licensed antiretrovirals.
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